A new study by a team of researchers from two Toronto hospitals found that children who spent more time on screens before age eight scored lower on standardized tests. The study's lead author says the ...

Gentle Full-Body Stretch | Day 12 of 21-Day Yoga Challenge Welcome to Day 12 of your 21-Day Yoga Challenge! This slow yoga flow for beginners and those over 40 is designed to improve flexibility, ...

Most teen boys are exposed to “digital masculinity,” with posts showing up in their feeds that criticize their body, their ...

New research reveals a seeming contradiction when it comes to kids who do and don't need vitamins to supplement their diets. Researchers at the University of California-Davis Children's Hospital found ...

Join me in this intermediate power yoga morning flow with no props required. Join the 30-Day Yoga & Pilates Morning Challenge: FREE WEEKLY YOGA CLASSES Good morning everyone! If you're still feeling a ...

Icotrokinra met the primary endpoint of clinical response at all three doses, with 36.5% of patients treated achieving endoscopic improvement and 30.2% achieving clinical remission at the highest dose ...

New research presented at the Annual Meeting of the European Association for the Study of Diabetes in Vienna, Austria (Sept 15–19) and simultaneously published in NEJM shows that daily treatment with ...

What makes the human brain different from that of other primates has long been a question. A new study suggests that the ...

Choose the right cardio equipment for your home gym — here's how the elliptical machine stacks up against the treadmill.

Biogen Inc. (Nasdaq: BIIB) and Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, today ...

You can’t buy a crayon with the amount spent on arts education in some schools – leaving pupils without the skills for ...

Incyte (Nasdaq: INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Opzelura ® (ruxolitinib) cream 1.5%, a topical Janus kinase (JAK) inhibitor, for the short-term and ...